FDA Awards Israeli Stem Cell Co Pluristem Orphan Drug Status – Jewish Business News
Jewish Business News |
FDA Awards Israeli Stem Cell Co Pluristem Orphan Drug Status
Jewish Business News Israeli placenta-based cell therapy developer Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) has been awarded orphan drug status by the US Food and Drug Administration (FDA) for its PLX-PAD cells treatment for severe preeclampsia. |
